The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure

ABSTRACT Introduction: Mineralocorticoid receptor antagonists (MRAs) have been accorded a class 1 indication for patients with chronic heart failure and a reduced left ventricular ejection fraction (HFREF) in both European and American guidelines. Uptake, however, has been less than optimal largely due to concerns about their safety, in particular the risk of hyperkalemia and renal dysfunction. Areas covered: This review presents the current state of affairs regarding the safety of MRAs in heart failure with reduced ejection fraction. Expert opinion: Careful patient selection and adherence to guideline-recommended inclusion and exclusion criteria, dosing, and serial monitoring of serum potassium and renal function, along with patient education regarding the potassium content of common foods, should minimize these risks and allow increased use of MRAs. Additionally, this may also result in a further reduction in cardiovascular mortality and hospitalizations for heart failure. The development of new non-steroidal MRAs, and especially new potassium binding molecules that are well tolerated and effective, hold the promise for increased safety and, therefore, increased and more prolonged use of MRAs in patients with heart failure, especially those with chronic kidney disease, diabetes mellitus, and the elderly.

[1]  E. Peterson,et al.  Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure. , 2015, JAMA.

[2]  G. Bakris,et al.  New Potassium Binders for the Treatment of Hyperkalemia: Current Data and Opportunities for the Future , 2015, Hypertension.

[3]  L. Ruilope,et al.  Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. , 2015, JAMA.

[4]  F. Eitner,et al.  Nonsteroidal antagonists of the mineralocorticoid receptor , 2015, Current opinion in nephrology and hypertension.

[5]  M. Freeman,et al.  Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial. , 2015, JAMA.

[6]  G. Bakris,et al.  Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. , 2015, The New England journal of medicine.

[7]  P. Lavin,et al.  Sodium zirconium cyclosilicate in hyperkalemia. , 2015, The New England journal of medicine.

[8]  F. Zannad,et al.  Regional differences in heart failure with preserved ejection fraction trials: when nephrology meets cardiology but east does not meet west. , 2015, Circulation.

[9]  Akshay S. Desai,et al.  Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial , 2015, Circulation.

[10]  M. Nuttall,et al.  Characterization of Structure and Function of ZS-9, a K+ Selective Ion Trap , 2014, PloS one.

[11]  B. Pitt,et al.  Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries. , 2014, International journal of cardiology.

[12]  P. Lavin,et al.  Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. , 2014, JAMA.

[13]  F. Eitner,et al.  Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury , 2014, Journal of cardiovascular pharmacology.

[14]  C. Morgan,et al.  Spironolactone use and higher hospital readmission for Medicare beneficiaries with heart failure, left ventricular ejection fraction <45%, and estimated glomerular filtration rate <45 ml/min/1.73 m(2.). , 2014, The American journal of cardiology.

[15]  Akshay S. Desai,et al.  Incidence, Predictors, and Outcomes Related to Hypo- and Hyperkalemia in Patients With Severe Heart Failure Treated With a Mineralocorticoid Receptor Antagonist , 2014, Circulation. Heart failure.

[16]  Sanjiv J Shah,et al.  Spironolactone for heart failure with preserved ejection fraction. , 2014, The New England journal of medicine.

[17]  W. Tang,et al.  Utilization pattern of mineralocorticoid receptor antagonists in contemporary patients hospitalized with acute decompensated heart failure: a single-center experience. , 2014, Journal of cardiac failure.

[18]  J. McMurray,et al.  Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). , 2013, Journal of the American College of Cardiology.

[19]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[20]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[21]  P. Ponikowski,et al.  Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial , 2013, European heart journal.

[22]  Ali Ahmed,et al.  Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction. , 2013, JACC. Heart failure.

[23]  Akshay S. Desai,et al.  Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). , 2012, Journal of the American College of Cardiology.

[24]  I. Piña,et al.  Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. , 2012, European heart journal.

[25]  Alexander Hillisch,et al.  Discovery of BAY 94‐8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases , 2012, ChemMedChem.

[26]  M. Banach,et al.  The meaning of hypokalemia in heart failure. , 2012, International journal of cardiology.

[27]  K. Chayama,et al.  Mineralocorticoid Receptor Blocker Eplerenone Improves Endothelial Function and Inhibits Rho‐Associated Kinase Activity in Patients With Hypertension , 2012, Clinical pharmacology and therapeutics.

[28]  M. Gheorghiade,et al.  Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes. , 2011, European heart journal.

[29]  Bertram Pitt,et al.  Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial , 2011, European heart journal.

[30]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[31]  M. Horie,et al.  Effect of eplerenone versus spironolactone on cortisol and hemoglobin A₁(c) levels in patients with chronic heart failure. , 2010, American heart journal.

[32]  T. Fahey,et al.  Spironolactone use and renal toxicity: population based longitudinal analysis , 2010, BMJ : British Medical Journal.

[33]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[34]  G. Bakris,et al.  Hypokalemia and Outcomes in Patients With Chronic Heart Failure and Chronic Kidney Disease: Findings From Propensity-Matched Studies , 2010, Circulation. Heart failure.

[35]  D. Mikhailidis,et al.  A Comparison of the Aldosterone‐blocking Agents Eplerenone and Spironolactone , 2009, Clinical cardiology.

[36]  M. Gheorghiade,et al.  A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. , 2007, European heart journal.

[37]  J. Beizer,et al.  Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. , 2005, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.

[38]  A. Struthers,et al.  What is the optimal serum potassium level in cardiovascular patients? , 2004, Journal of the American College of Cardiology.

[39]  B. Pitt,et al.  Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[40]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[41]  G. Tomaselli,et al.  Electrophysiological remodeling in hypertrophy and heart failure. , 1999, Cardiovascular research.

[42]  F. Zannad.  Angiotensin-converting enzyme inhibitor and spironolactone combination therapy. New objectives in congestive heart failure treatment. , 1993, The American journal of cardiology.

[43]  J. Ohayon,et al.  Global left ventricular function and regional wall motion in pure mitral stenosis‐Left ventricular function in pure mitral stenosis , 1984, Clinical cardiology.

[44]  Akshay S. Desai,et al.  Incidence , Predictors and Outcomes Related to Hypo and Hyperkalemia in Severe Heart Failure Patients Treated with a Mineralocorticoid Receptor Antagonist , 2014 .

[45]  Van Veldhuisen,et al.  Safety and efficacy of eplerenone in patients at high-risk for hyperkalemia and / or worsening renal function : Analyses of EMPHASIS-HF study subgroups , 2013 .

[46]  M. Cheitlin.  Eplerenone Survival Benefits in Heart Failure Patients Post-Myocardial Infarction Are Independent From its Diuretic and Potassium-Sparing Effects: Insights From an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) Substudy , 2012 .

[47]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[48]  B. Pitt.  Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). , 1996, The American journal of cardiology.

[49]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.